secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-06-15T13:14:40+00:00
Accession:  0001193125-26-270384
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 2.05, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene cuts workforce ~50%, CMO and CFO resign; Q2 loss widens to $30.2M
------------------------------------------------------------------------

- Workforce reduction of ~50% to streamline ops and preserve cash; restructuring costs est. $5.7-$6.4M cash plus $4.7-$5.0M non-cash stock comp.
- CFO Ryan Daws to depart July 15, 2026; Kathleen Richton appointed SVP Finance and principal financial officer.
- CMO Dr. Hussein Sweiti resigned effective June 14; Dr. William Grossman named interim CMO.
- Q2 net loss $30.2M ($0.43/share) vs $25.8M ($0.51/share) YoY; cash, equivalents and marketable securities $285.2M.
- LEGEND Cohort 1: 54% CR at any time; awaiting 12-month durability data; BLA filing and FDA meeting planned for 2H 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/0001193125-26-270384-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526270384/engn-20260613.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-270384

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer